Antiviral drug “Nobazit” from “Avexima”, the Russian pharmaceutical company, at the main musical event of the year – the National Music Award “Golden Gramophone”.

27.12.2022

The modern antiviral drug “Nobazit” has become the official sponsor of the National Music Award “Golden Gramophone”, which took place on December 10, 2022. As a gift from the sponsor, the singer and composer Dmitry Malikov received a supply of the antiviral drug “Nobazit”.

Dmitry Malikov, even despite the temperature and illness, found the strength to perform and did not disappoint numerous fans, unlike many performing artists, who, during the influenza epidemic, were forced to miss the ceremony. “You have chosen the right performing artist to give the award to. This is exactly what I need right now”, the singer said, accepting the gift from Anna Karutina, the Public Relations and Advertising Department Head of the “Avexima”, OJSC.

Interactive photo zones and many other surprises from the “Nobazit” brand were placed in the VTB Arena foyer for the solemn ceremony guests.

*Nobazit is an antiviral agent. The maximum concentration of the active substance is reached already 2-2.5 hours after administration, which means readiness to act against respiratory viruses. It effectively suppresses the influenza viruses action and other causative agents of acute respiratory viral infections (ARVI) by directly (inhibiting) affecting the process of virus penetration through the cell membrane¹.

Leading healthcare experts consider Nobazit (INN: Enisamium Iodide) as a standard in the field of respiratory viral diseases therapy:

·         Nobazit is included in the Federal Clinical Guidelines “Acute Respiratory Viral Infections (ARVI) in adults”²

·         Nobazit is included in the temporary guidelines of the Ministry of Health of the Russian Federation “DRUG THERAPY OF ACUTE RESPIRATORY VIRAL INFECTIONS (ARVI) IN OUTPATIENT PRACTICE DURING THE COVID-19 EPIDEMIC”³

·         Nobazit is included in the Methodological Guidelines “Influenza and other acute respiratory viral infections during the ongoing COVID-19 pandemic: prevention and treatment” of the Federal Medical and Biological Agency⁴

·         Nobazit is included by experts of the World Health Organization in the ATC classification in the section of drugs with direct antiviral action (J05A – Direct acting antivirals, J05AX17)⁵

·         Increases the body's resistance to viral infections¹

·         Reduces acute clinical manifestations of viral intoxication, contributes to the disease duration reduction.¹

·         High susceptibility of various types of respiratory viruses to enisamium iodide (Nobazit), including the currently predominant strain⁶  H1N1pdm09 (swine flu), to Enisamium Iodide (Nobazit) has been established at the Pasteur Institute in 2020⁷.

1.      Instructions for Medical Use of Nobazit, film-coated tablets, 250 mg. RU: LP-003508

2.      Clinical Guidelines of the Ministry of Health of the Russian Federation “Acute Respiratory Viral Infections (ARVI) in adults”. https://cr.minzdrav.gov.ru/clin_recomend Placement date: February 15, 2022

3.      TEMPORARY GUIDELINES “INTERIM GUIDELINES: DRUG THERAPY FOR ACUTE RESPIRATORY VIRAL INFECTIONS (ARVI) IN OUTPATIENT PRACTICE DURING THE COVID-19 EPIDEMIC.” VERSION 2 (APRIL 16, 2020)

4.      Methodological Guidelines “Influenza and other acute respiratory viral infections during the ongoing COVID-19 pandemic: prevention and treatment”, the Federal Medical and Biological Agency, Approval Date: October 10, 2022..

5.      https://www.whocc.no/atc_ddd_index/?code=J05AX17 . Date of access: December 21, 2022

6.      https://www.influenza.spb.ru/system/epidemic_situation/laboratory_diagnostics/

7.      Zarubaev V.V., Slita A.V., Sinegubova E.O. and others. Antiviral activity of Enisamium Iodide against influenza and ARVI viruses in vitro on various cell lines. Therapeutic archive. 2020; 92 (11): 45–50. DOI: 10.26442/00403660.2020.11.00087.